What Is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed in the 1980s at the University of Arizona by Victor Hruby and colleagues as part of a systematic effort to create potent, metabolically stable melanocortin receptor agonists. The peptide sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a molecular weight of approximately 1024 Da.
MT-II is a non-selective agonist, meaning it activates all five melanocortin receptor subtypes (MC1R through MC5R) with varying potency. This broad receptor engagement produces a complex pharmacological profile that includes effects on pigmentation, appetite, energy balance, and sexual function. Understanding MT-II requires understanding the melanocortin receptor system and how non-selective versus selective activation produces different research and pharmacological profiles.
The Melanocortin Receptor System
The melanocortin system comprises five G-protein coupled receptors (MC1R–MC5R), their endogenous agonists (alpha-MSH, beta-MSH, gamma-MSH, and ACTH, all derived from the proopiomelanocortin (POMC) precursor protein), and the endogenous antagonists agouti-related peptide (AgRP) and agouti signaling protein (ASIP). All melanocortin receptors are class A GPCRs that couple primarily to Gs, activating adenylyl cyclase and raising intracellular cAMP.
MC1R is expressed primarily on melanocytes in the skin and hair follicles, as well as on immune cells (monocytes, macrophages, dendritic cells). Activation of MC1R is the primary signal driving melanin synthesis (melanogenesis), specifically the production of eumelanin, the brown-black photoprotective pigment. MC1R also mediates anti-inflammatory effects in immune cells by suppressing NF-kB signaling and pro-inflammatory cytokine production. MC1R polymorphisms are strongly associated with fair skin, red hair, and increased melanoma susceptibility.
MC2R is the ACTH receptor, expressed primarily in the adrenal cortex, where it mediates cortisol and aldosterone synthesis. MT-II has minimal activity at MC2R due to the requirement for the full ACTH sequence for efficient MC2R activation.
MC3R is expressed in the hypothalamus (particularly the arcuate nucleus), brainstem, and peripheral tissues including the gastrointestinal tract and placenta. MC3R plays a role in energy homeostasis, with knockout studies showing increased adiposity and altered nutrient partitioning. MC3R appears to function as a modulatory receptor, influencing the sensitivity and set-point of energy balance circuits rather than directly driving acute feeding or satiety responses.
MC4R is expressed broadly in the central nervous system, with high density in the hypothalamus (paraventricular nucleus), brainstem (nucleus tractus solitarius), cortex, and spinal cord. MC4R is the primary melanocortin receptor mediating appetite suppression, energy expenditure regulation, and autonomic nervous system effects on cardiovascular function. MC4R also mediates effects on sexual function, particularly erectile response and sexual arousal, through spinal cord and brainstem circuits. The identification of MC4R-mediated sexual function effects during MT-II research directly led to the development of bremelanotide (PT-141), a selective MC4R agonist developed as a therapeutic agent for sexual dysfunction.
MC5R is expressed in sebaceous glands, adrenal glands, adipose tissue, and various exocrine glands. MC5R activation stimulates sebum production and influences exocrine secretion. MC5R knockout mice show defective water repulsion in fur due to impaired sebaceous gland function.
MT-II vs Melanotan I (Afamelanotide)
Melanotan I (also known as afamelanotide or [Nle4, D-Phe7]-alpha-MSH) is a linear tridecapeptide analog of alpha-MSH that is highly selective for MC1R. Unlike MT-II's cyclic structure, MT-I retains the linear 13-amino acid framework of alpha-MSH with just two substitutions (norleucine at position 4 and D-phenylalanine at position 7) that enhance metabolic stability and receptor affinity.
The practical differences are significant. MT-I's MC1R selectivity means it primarily drives melanogenesis without the MC4R-mediated effects on appetite, sexual function, and cardiovascular parameters that MT-II produces. MT-I has been approved as a therapeutic agent (afamelanotide/Scenesse) for the prevention of phototoxicity in patients with erythropoietic protoporphyria, a rare genetic disorder of heme metabolism. MT-II's non-selective profile produces a broader spectrum of effects but with less predictability and more potential for off-target consequences.
For research purposes, the choice between MT-I and MT-II depends on the question being investigated. Pure melanogenesis studies benefit from MT-I's selectivity. Research investigating multi-receptor melanocortin signaling, MC4R-mediated effects, or the integrated physiological response to broad melanocortin activation requires MT-II.
The Melanogenesis Pathway
MC1R activation by alpha-MSH or MT-II triggers a well-characterized intracellular signaling cascade in melanocytes. MC1R couples to Gs, activating adenylyl cyclase and increasing intracellular cAMP levels. cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB translocates to the nucleus and activates transcription of the MITF (microphthalmia-associated transcription factor) gene, the master regulator of melanocyte development and function.
MITF, in turn, drives the expression of three key melanogenic enzymes: tyrosinase (the rate-limiting enzyme that catalyzes the first two steps of melanin synthesis), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2/DCT). The net result is increased synthesis and melanization of melanosomes (the organelles in which melanin is produced and stored), followed by transfer of mature melanosomes to surrounding keratinocytes, producing visible skin and hair pigmentation.
Importantly, MC1R activation specifically promotes eumelanin (brown-black pigment) production over pheomelanin (red-yellow pigment). Eumelanin provides superior photoprotection through UV absorption and free radical scavenging, while pheomelanin may actually contribute to oxidative DNA damage. The switch from pheomelanin to eumelanin synthesis is one of the most significant effects of MC1R activation.
Published Research Findings
MT-II produces significant and measurable increases in skin pigmentation (tanning) independent of UV exposure, though UV exposure enhances and accelerates the response. This UV-independent melanogenesis is mediated entirely through the MC1R-cAMP-MITF-tyrosinase cascade described above.
The MC4R-mediated effects on sexual function, identified during early MT-II clinical studies, led directly to the development of bremelanotide (PT-141), which received FDA approval for hypoactive sexual desire disorder. This represents one of the most significant drug development outcomes from melanocortin peptide research.
MC4R activation by MT-II also influences appetite through hypothalamic circuits, producing measurable reductions in food intake in both animal models and human studies. The melanocortin appetite pathway (POMC neurons releasing alpha-MSH that activates MC4R on downstream neurons in the paraventricular nucleus) is one of the best-characterized central appetite regulatory circuits.
Safety Considerations in Research
MT-II's non-selective receptor profile means that effects are distributed across multiple organ systems. Cardiovascular effects (modest blood pressure elevation, flushing) are mediated through MC4R autonomic regulation. Nausea, reported in many clinical studies, may relate to MC4R activation in the area postrema. The broad receptor engagement makes MT-II less precise than selective agonists for investigating individual receptor contributions to specific physiological processes.
Practical Research Notes
MT-II is available from MiPeptidos as lyophilized powder at 99%+ HPLC purity. The tryptophan residue makes MT-II light-sensitive — protect from UV and visible light during handling and storage. Store lyophilized at -20°C wrapped in foil. Reconstitute with bacteriostatic water; store at 2–8°C protected from light.
Disclaimer
For research purposes only. Not for human consumption.